SymbolSDGR
NameSCHRODINGER, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1540 BROADWAY,24TH FLOOR, NEW YORK, New York, 10036, United States
Telephone+1 212 295-5800
Fax
Email
Websitehttps://www.schrodinger.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001490978
Description

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Additional info from NASDAQ:
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

2026-08-14 12:30

Schrödinger, Inc. - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-14 12:30

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-05 20:05

Schrödinger, Inc. - Schrödinger Reports Second Quarter 2026 Financial Results

Read more
2026-08-05 20:05

Schrödinger Reports Second Quarter 2026 Financial Results

Read more
2026-08-05 12:30

Schrödinger, Inc. - Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Read more
2026-08-05 12:30

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Read more
2026-07-27 11:30

Schrödinger, Inc. - Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery

Read more
2026-07-22 12:30

Schrödinger, Inc. - Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

Read more
2026-07-20 12:30

Schrödinger, Inc. - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-07-17 21:09

Jain Rachit 🔴 sold 875 shares of Schrodinger, Inc. (SDGR) at $15.60 Transaction Date: Jul 16, 2026 | Filing ID: 000004

Read more